Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Topic Coronavirus Clinical Trials Vaccines

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Lilly's Olumiant Cuts COVID-19 Hospital Stays By One Day

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.

Topic Coronavirus clinical-trials research

Citeline

The Future of Clinical Trials From the Investigator Perspective Webinar

Listen to our podcast “The Future of Clinical Trials From the Investigator Perspective” from earlier this year and register for our upcoming webinar to learn new developments

Topic Clinical Trials Coronavirus

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Pharma Stands Up To Trump Pressure With COVID-19 Vaccines Science Pledge

CEOs from the most advanced vaccines developers pledge to maintain standards – for the sake of safety, efficacy and public trust in vaccines

Topic clinical-trials

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To 'Follow Science' In Vaccine Trials

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

Topic Coronavirus Clinical Trials Research & Development

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Coronavirus Update: End Of The Road For Kevzara In COVID-19

Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials

Topic Coronavirus clinical-trials

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Coronavirus Update: Moderna In Advanced Talks With Europe On Vaccine Supplies

The deal would include an option for expansion to 160 million doses of the mRNA-based vaccine.

Topic Coronavirus clinical-trials vaccines

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?

After the FDA's emergency use authorization for convalescent plasma, pushed on by President Trump, an alliance of firms is working with the NIH to conduct a robust study of a potentially more potent alternative.

Topic Coronavirus Clinical Trials